Oral Omilancor Treatment Ameliorates Clostridioides difficile Infection During IBD Through Novel Immunoregulatory Mechanisms Mediated by LANCL2 Activation.

Nuria Tubau-JuniJosep Bassaganya-RieraAndrew J LeberSameeksha S AlvaRaquel Hontecillas

Published in: Inflammatory bowel diseases (2023)

These data support the development of omilancor as a novel host-targeted, antimicrobial-free immunoregulatory therapeutic for the treatment of IBD patients with C. difficile-associated disease and pathology with the potential to address the unmet clinical needs of ulcerative colitis and Crohn's disease patients with concomitant CDI.

Keyphrases

ulcerative colitis
clostridium difficile
staphylococcus aureus
electronic health record
mouse model
machine learning
deep learning